AZD2811 + Azacitidine + Venetoclax
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukaemia
Conditions
Acute Myeloid Leukaemia
Trial Timeline
Jul 31, 2017 → Mar 25, 2021
NCT ID
NCT03217838About AZD2811 + Azacitidine + Venetoclax
AZD2811 + Azacitidine + Venetoclax is a phase 1 stage product being developed by AstraZeneca for Acute Myeloid Leukaemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03217838. Target conditions include Acute Myeloid Leukaemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03217838 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukaemia